JP7812612B2 - 抗ｃｄ３８抗体の皮下投与 - Google Patents

抗ｃｄ３８抗体の皮下投与

Info

Publication number
JP7812612B2
JP7812612B2 JP2020560111A JP2020560111A JP7812612B2 JP 7812612 B2 JP7812612 B2 JP 7812612B2 JP 2020560111 A JP2020560111 A JP 2020560111A JP 2020560111 A JP2020560111 A JP 2020560111A JP 7812612 B2 JP7812612 B2 JP 7812612B2
Authority
JP
Japan
Prior art keywords
antibody
cells
seq
amino acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510737A5 (https=
JP2021510737A (ja
JPWO2019140410A5 (https=
Inventor
ダール、マーティン
フェディク、エリック
エヴァンス、ロバート
ザオ、リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2021510737A publication Critical patent/JP2021510737A/ja
Publication of JP2021510737A5 publication Critical patent/JP2021510737A5/ja
Publication of JPWO2019140410A5 publication Critical patent/JPWO2019140410A5/ja
Priority to JP2023190427A priority Critical patent/JP2024023247A/ja
Application granted granted Critical
Publication of JP7812612B2 publication Critical patent/JP7812612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020560111A 2018-01-12 2019-01-14 抗ｃｄ３８抗体の皮下投与 Active JP7812612B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023190427A JP2024023247A (ja) 2018-01-12 2023-11-07 抗ｃｄ３８抗体の皮下投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862617146P 2018-01-12 2018-01-12
US62/617,146 2018-01-12
PCT/US2019/013547 WO2019140410A1 (en) 2018-01-12 2019-01-14 Subcutaneous dosing of anti-cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023190427A Division JP2024023247A (ja) 2018-01-12 2023-11-07 抗ｃｄ３８抗体の皮下投与

Publications (4)

Publication Number Publication Date
JP2021510737A JP2021510737A (ja) 2021-04-30
JP2021510737A5 JP2021510737A5 (https=) 2022-02-24
JPWO2019140410A5 JPWO2019140410A5 (https=) 2022-02-24
JP7812612B2 true JP7812612B2 (ja) 2026-02-10

Family

ID=65529766

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560111A Active JP7812612B2 (ja) 2018-01-12 2019-01-14 抗ｃｄ３８抗体の皮下投与
JP2023190427A Pending JP2024023247A (ja) 2018-01-12 2023-11-07 抗ｃｄ３８抗体の皮下投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023190427A Pending JP2024023247A (ja) 2018-01-12 2023-11-07 抗ｃｄ３８抗体の皮下投与

Country Status (11)

Country Link
US (2) US12371506B2 (https=)
EP (1) EP3737702A1 (https=)
JP (2) JP7812612B2 (https=)
KR (1) KR20210006321A (https=)
CN (1) CN112739715A (https=)
AU (1) AU2019208102B2 (https=)
BR (1) BR112020014052A2 (https=)
CA (1) CA3088199A1 (https=)
CO (1) CO2020008561A2 (https=)
MX (1) MX2020007429A (https=)
WO (1) WO2019140410A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
US12181485B2 (en) * 2020-09-10 2024-12-31 CASI Pharmaceuticals, Inc Methods of blood screening
CN116635420A (zh) * 2020-09-10 2023-08-22 英创远达制药公司 血液筛查方法
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
CN121127494A (zh) 2023-01-06 2025-12-12 武田药品工业株式会社 用于治疗自身免疫性疾病的抗cd38抗体
KR20250052963A (ko) 2023-10-12 2025-04-21 주식회사 쿠노소프트 글로벌 지능형 b2b 기업매칭 시스템
WO2025160986A1 (en) * 2024-02-02 2025-08-07 Keymed Biosciences (Chengdu) Co., Ltd. An anti-cd38 monoclonal antibody and application thereof
WO2025193746A1 (en) 2024-03-12 2025-09-18 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
WO2025213286A1 (zh) * 2024-04-07 2025-10-16 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用
WO2025235919A1 (en) 2024-05-09 2025-11-13 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509837A (ja) 2010-12-30 2014-04-24 武田薬品工業株式会社 抗ｃｄ３８抗体
JP2014514345A (ja) 2011-05-02 2014-06-19 イミューノメディクス、インコーポレイテッド 少容量投与用のアロタイプ選択抗体の限外濾過濃縮

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
RU2570559C2 (ru) 2007-12-17 2015-12-10 Пфайзер Лимитед Лечение интерстициального цистита
WO2010008726A1 (en) 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
US8399630B2 (en) 2008-08-20 2013-03-19 Centocor Ortho Biotech Inc. Engineered anti-IL-13 antibodies, compositions, methods and uses
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
GB2486424A (en) 2010-12-13 2012-06-20 Univ Sussex Markers for plasma cell disorders
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
GB201203938D0 (en) 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system
GB201212900D0 (en) 2012-07-20 2012-09-05 Binding Site Group The Ltd Triage scoring system
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
MX381725B (es) 2013-07-30 2025-03-13 Sbi Biotech Co Ltd Medicamento que comprende anticuerpo anti-fosfolipasa d4.
SG10201803288RA (en) 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
PT3294769T (pt) 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
US20210171650A1 (en) 2019-05-14 2021-06-10 Sanofi Methods of administering anti-cd38 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509837A (ja) 2010-12-30 2014-04-24 武田薬品工業株式会社 抗ｃｄ３８抗体
JP2014514345A (ja) 2011-05-02 2014-06-19 イミューノメディクス、インコーポレイテッド 少容量投与用のアロタイプ選択抗体の限外濾過濃縮

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, HISTORY OF CHANGES FOR STUDY: NCT02219256, CLINICAL TRIALS.GOV ARCHIVE[ONLINE], 2017年03月22日, PAGE(S):1 - 12, <URL:https://clinicaltrials.gov/ct2/history/NCT02219256?V_8=View#StudyPageTop>
J Immunol, 2017年, Vol.198 (1_Supplement): 224.20, p.1-2

Also Published As

Publication number Publication date
AU2019208102B2 (en) 2025-10-09
JP2021510737A (ja) 2021-04-30
MX2020007429A (es) 2020-10-15
US12371506B2 (en) 2025-07-29
US20210388103A1 (en) 2021-12-16
KR20210006321A (ko) 2021-01-18
AU2019208102A1 (en) 2020-07-02
BR112020014052A2 (pt) 2020-12-08
JP2024023247A (ja) 2024-02-21
CO2020008561A2 (es) 2020-10-30
CA3088199A1 (en) 2019-07-18
EP3737702A1 (en) 2020-11-18
RU2020126723A3 (https=) 2022-02-14
US20260103534A1 (en) 2026-04-16
CN112739715A (zh) 2021-04-30
RU2020126723A (ru) 2022-02-14
WO2019140410A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
JP7812612B2 (ja) 抗ｃｄ３８抗体の皮下投与
JP7526099B2 (ja) 抗ｃｄ３８抗体の皮下投薬
JP6840813B2 (ja) 抗ｃｄ３８抗体
JP2023525085A (ja) がんを治療するための組成物および方法
RU2782950C2 (ru) Подкожное введение анти-cd38 антител
RU2810953C2 (ru) Подкожное дозирование антител к cd38
US20250197505A1 (en) Anti-cd94 antibodies and methods of use thereof
HK40036964A (en) Subcutaneous dosing of anti-cd38 antibodies
WO2026090536A1 (en) Methods and uses for treating nk cell or t-cell lymphomas or leukemias with anti-cd94 antibodies
RU2787629C2 (ru) Способы и материалы для оценки ответа на терапию против плазмобластов и плазматических клеток

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231221

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260129

R150 Certificate of patent or registration of utility model

Ref document number: 7812612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150